Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
RESEARCH TRIANGLE PARK, N.C., Oct. 19, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a...
-
RESEARCH TRIANGLE PARK, N.C., Oct. 10, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the last patient has been randomized...
-
RESEARCH TRIANGLE PARK, N.C., Oct. 03, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options...
-
RESEARCH TRIANGLE PARK, N.C., Sept. 07, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that Jack Bailey, G1’s Chief Executive...
-
RESEARCH TRIANGLE PARK, N.C., Sept. 06, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will host a virtual...
-
RESEARCH TRIANGLE PARK, N.C., Sept. 01, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options...
-
- Achieved $8.7 Million in Net Revenue from Sales of COSELA® (trilaciclib) in the Second Quarter of 2022 and $10.6 Million in Total Revenue - - Completed Patient Enrollment in Pivotal Phase 3 Trial...
-
RESEARCH TRIANGLE PARK, N.C., Aug. 01, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options...
-
RESEARCH TRIANGLE PARK, N.C., Aug. 01, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two...
-
RESEARCH TRIANGLE PARK, N.C., July 25, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the appointment of Norman E. “Ned”...